Pharming Group NV (PHAR)
12.12
+0.35
(+2.97%)
USD |
NASDAQ |
Aug 26, 14:33
Pharming Group Shareholders Equity (Quarterly) : 257.03M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 257.03M |
| March 31, 2026 | 268.96M |
| December 31, 2025 | 277.10M |
| September 30, 2025 | 264.64M |
| June 30, 2025 | 227.33M |
| March 31, 2025 | 214.00M |
| December 31, 2024 | 221.06M |
| September 30, 2024 | 225.79M |
| June 30, 2024 | 209.85M |
| March 31, 2024 | 205.94M |
| December 31, 2023 | 218.78M |
| September 30, 2023 | 209.94M |
| June 30, 2023 | 200.37M |
| March 31, 2023 | 199.34M |
| December 31, 2022 | 204.64M |
| September 30, 2022 | 200.25M |
| June 30, 2022 | 199.67M |
| March 31, 2022 | 194.02M |
| December 31, 2021 | 192.92M |
| September 30, 2021 | 193.55M |
| June 30, 2021 | 198.07M |
| March 31, 2021 | 186.36M |
| December 31, 2020 | 182.77M |
| September 30, 2020 | 159.78M |
| June 30, 2020 | 143.28M |
| Date | Value |
|---|---|
| March 31, 2020 | 126.86M |
| December 31, 2019 | 117.50M |
| September 30, 2019 | 98.64M |
| June 30, 2019 | 88.25M |
| March 31, 2019 | 77.55M |
| December 31, 2018 | 70.59M |
| September 30, 2018 | 55.95M |
| June 30, 2018 | 47.48M |
| March 31, 2018 | 38.87M |
| December 31, 2017 | 22.58M |
| September 30, 2017 | 7.344M |
| June 30, 2017 | 7.715M |
| March 31, 2017 | 30.95M |
| December 31, 2016 | 28.97M |
| September 30, 2016 | 16.84M |
| June 30, 2016 | 20.17M |
| March 31, 2016 | 23.97M |
| December 31, 2015 | 25.90M |
| September 30, 2015 | 28.55M |
| June 30, 2015 | 31.08M |
| March 31, 2015 | 31.44M |
| December 31, 2014 | 36.11M |
| September 30, 2014 | 20.06M |
| June 30, 2014 | 16.69M |
| March 31, 2014 | 9.801M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ProQR Therapeutics NV | 90.87M |
| NewAmsterdam Pharma Co. NV | 631.42M |
| argenx SE | -- |
| DBV Technologies SA | -- |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 467.98M |
| Total Liabilities (Quarterly) | 210.95M |
| Debt to Equity Ratio | 0.4931 |
| Current Ratio | 3.010 |
| Net Debt Paydown Yield | -0.15% |